A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Public ClinicalTrials.gov record NCT01268150. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Study identification
- NCT ID
- NCT01268150
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 56 participants
Conditions and interventions
Interventions
- Eribulin mesylate Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2011
- Primary completion
- Feb 29, 2012
- Completion
- Jul 31, 2013
- Last update posted
- Jun 21, 2023
2011 – 2013
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Miami | Miami | Florida | 33136 | — |
| Augusta Oncology Associates | Augusta | Georgia | 30901 | — |
| Central Georgia Cancer Care | Macon | Georgia | 31088 | — |
| Northwest Georgia Oncology Centers, P.C. | Marietta | Georgia | 30060 | — |
| Central Indiana Cancer Centers | Indianapolis | Indiana | 46219 | — |
| Missouri Cancer Associates | Columbia | Missouri | 65201 | — |
| Hematology Oncology Centers of Northern Rockies | Billings | Montana | 59101 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12206 | — |
| Weill Cornell Medical Center | New York | New York | 10021 | — |
| Northwest Cancer Specialists, P.C. | Portland | Oregon | 97225 | — |
| The West Clinic | Memphis | Tennessee | 38120 | — |
| Texas Oncology- Bedford | Bedford | Texas | 76022 | — |
| Texas Oncology - Medical City Dallas | Dallas | Texas | 75230-2510 | — |
| Texas Oncology-Dallas Presbyterian Hospital | Dallas | Texas | 75231 | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | 78217 | — |
| Texas Oncology- Tyler | Tyler | Texas | 75702 | — |
| Columbia Basin Hematology and Oncology | Kennewick | Washington | 99336 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01268150, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2023 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01268150 live on ClinicalTrials.gov.